| Literature DB >> 35308223 |
Hongzhang Ge1,2,3, Chao Xu1,2,3, Haitao Chen1,2,3, Ling Liu1,2,3, Lei Zhang1,2,3, Changhong Wu4, Yi Lu5, Qinghua Yao1,2,3,4,5.
Abstract
Colorectal cancer (CRC) is the third most common type of cancer worldwide. Distant metastasis is the major cause of cancer-related mortality in patients with CRC. Epithelial-mesenchymal transition (EMT) is a critical process triggered during tumor metastasis, which is also the main impetus and the essential access within this duration. Therefore, targeting EMT-related molecular pathways has been considered a novel strategy to explore effective therapeutic agents against metastatic CRC. Traditional Chinese medicines (TCMs) with unique properties multi-target and multi-link that exert their therapeutic efficacies holistically, which could inhibit the invasion and metastasis ability of CRC cells via inhibiting the EMT process by down-regulating transforming growth factor-β (TGF-β)/Smads, PI3K/Akt, NF-κB, Wnt/β-catenin, and Notch signaling pathways. The objective of this review is to summarize and assess the anti-metastatic effect of TCM-originated bioactive compounds and Chinese medicine formulas by mediating EMT-associated signaling pathways in CRC therapy, providing a foundation for further research on the exact mechanisms of action through which TCMs affect EMT transform in CRC.Entities:
Keywords: EMT-related signaling pathways; Traditional Chinese medicines; colorectal cancer; epithelial-mesenchymal transition; tumor metastasis
Year: 2022 PMID: 35308223 PMCID: PMC8931761 DOI: 10.3389/fphar.2022.842295
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1Key molecular targets and related-signaling pathways during the EMT program involved in the inhibition of migratory and invasive characteristics of CRC by TCMs. Notes: Several cell-intrinsic signalings cooperate to induce the expression of EMT-TFs containing Snail, Slug, ZEB1/2, and Twist, the expressions of which are induced by the above-mentioned signaling pathways, including TGF-β/Smads, Notch, Wnt/β-catenin, PI3K/Akt, and NF-κB, ultimately leading to transformation to the mesenchymal cell state. In response to TGF-β, Smad2/3 is activated and forms a protein complex with Smad4, and promotes the transcription of EMT-TFs. the expression of which is induced by various signaling pathways. The TGF-β molecular pathway also collaborates with the PI3K/AKT pathway, which in turn triggers the activation of the mTOR complex and NF-κB. On the other hand, AKT can restrain the function of GSK-3β, a kinase that inhibits nuclear translocation of ß-catenin and EMT-TFs Snail and Slug in Smad-independent pathways. Furthermore, MMP-2 expression is positively controlled by Smad2 whilst MMP-9 is modulated via NF-κB p65/p50 transcription signaling in tumor tissues and cells of CRC. The miR-200 family can down-regulate ZEB1/2 expression, and miR-200 can be blocked by Akt, which is triggered by most EMT-associated signalings. Wnt signaling promotes EMT programme by repressing GSK-3β through DSH to stabilize ß-catenin, which translocates into the nucleus to engage the transcription factors TCF and LEF and facilitate EMT-related genes expression. Additionally, Notch signaling also participates in EMT progression, behaving as interactions of Delta-like or Jagged ligands with Notch receptors initiate signaling through the proteolytic release of the Notch ICD, and then modulates target gene expression.
Targeting of EMT-related signaling pathways involved in metastatic CRC by natural bioactive compounds in vitro and in vivo.
| Compound names | Cell lines/animal models | Effective dose | Mechanisms of action | References |
|---|---|---|---|---|
| Curcumin | rHCT-116 cells | 5, 10, 20, and 40 μmol/L | Inhibit EMT progress; E-cadherin, |
|
| SW620 cells | 10, 20, and 40 μmol/L | Inhibit tumor metastasis; vimentin and CXCR4 (↓); E-cadherin, NKD2 (↑) |
| |
| SW620 and HT29 cells | / | Repress migration and invasion; EPM5, Snail, Slug, and ZEB1/2, and vimentin (↓); miR-200c, CDH1 (↑) |
| |
| SW480 cells | 0.1, 0.2, and 0.4 μmol/L | Suppress EMT transform; Wnt3a, Snail1, and Twist |
| |
| N-cadherin, and vimentin, | ||||
| Quercetin | CT-26 cells | 0.1, 1, and 10 μmol/L | Repress tumor metastasis and invasion; N-cadherin |
|
| CT-26 cells-induced lung metastases mice model | 10, 50 mg/kg | β-catenin, Snail, MMP-2, and MMP-9 (↓); E-cadherin (↑) | ||
| SW480 cells | 25, 50, and 100 μmol/L | Repress EMT-like phenotypes and tumor metastasis; Twist1 and vimentin (↓); E-cadherin (↑) |
| |
| Resveratrol | HCT116 and HCT116R cells | 1, 5, and 10 μmol/L | Restrain the tumor invasion; NF-κB, vimentin, Slug, MMP-9, and caspase-3 (↓); E-cadherin (↑) |
|
| HCT116 and HCT116R cells | 5 μmol/L | Suppress invasion; NF-κB, MMP-9, CXCR4, vimentin, and Slug (↓); E-cadherin (↑) |
| |
| HCT116, RKO, and SW480 cells | 5 μmol/L | Inhibit tumor migration and invasion; NF-κB, vimentin, and Slug (↓); E-cadherin (↑) |
| |
| LoVo cells | 6, 12 μmol/L | Reduce the rate of lung and hepatic metastases; p-Smad2/3, Snail, Slug, vimentin, MMP-2, and MMP-9 (↓); Smad2/3 and E-cadherin (↑) |
| |
| LoVo cells-induced lung metastases mice model | 50, 100, and 150 mg/kg | |||
| Resveratrol | SW480 and SW620 cells | 15 μmol/L | Inhibit CRC cell migration and invasion; N-cadherin, p-AKT1, p-GSK-3β, and Snail (↓); E-cadherin (↑) |
|
| Epidermal growth factor-induced EMT mice model | 150 mg/kg | |||
| HCT-116 cells | 30 μmol/L | Hinder the tumor migration and invasion; vimentin and ZEB1 (↓); miR-200c, E-cadherin (↑) |
| |
| Berberine | EMT-like HcoEpiC cells | 25, 50, and 100 μg/ml | Inhibit EMT program; TβRI, TβRII, Smad2/p-Smad2, Smad3/p-Smad3, ZEB1, and Snail (↓) |
|
| HCA-7 cells | 10, 30 μmol/L | Suppress EMT progression; Snai2 and TIMP1 (↓) |
| |
| Demethyleneberberine | HCT-116 cells | 6, 12, and 18 μmol/L | Promote apoptosis and reverse EMT process; p-Smad2 and p-Smad3 (↓), E-cadherin and ZO-1 (↑) |
|
| Ginsenoside Rb2 | HCT116 and SW620 cells | 0.1, 1, and 10 μg/ml | Inhibit tumor metastasis and EMT program; TGF-β1, Smad4, and p-Smad2/3 (↓) |
|
| HT29 and SW620 CRC cells | 10, 50, and 100 μmol/L | Decrease tumor metastasis and invasion; Snail, Twist, fibronectin, vimentin, and MMP-2 (↓), E-cadherin (↑) |
| |
| Ginsenoside Rd | HT29 and SW620 cells | 10, 50, and 100 μmol/L | Reduce the migration, invasion, and wound-healing abilities; Snail, Twist, fibronectin, N-Cadherin, and p-EGFR (↓); EGFR (↑) |
|
| Ginsenoside Rg3 | HCT15 and SW48 cells | 100 μmol/L | Inhibit tumor invasion and metastasis; vimentin, Snail, NICD, and Hes1 (↓); E-cadherin (↑) |
|
| HCT15 cells-induced metastasis mice model | 10 mg/kg | |||
| Ginsenoside Rg3R | HT29 and SW620 cells | 10, 50, and 100 μmol/L | Inhibit tumor migration and invasion; EGFR, fibronectin, Snail, and MMP-2 (↓), E-cadherin (↑) |
|
| HT29 cells-induced metastases mice model | 5 mg/kg | |||
| Triptolide | HT-29 and SW480 CRC cells | 10, 50, and 100 nmol/L | Reduce migratory capacity and repress the growth of primary tumor xenografts; Snail, vimentin, and N-cadherin (↓) |
|
| E-cadherin (↑) | ||||
| CD133+/CD44 + colon cancer stem cells | 25, 50, 75, and 100 nmol/L | Suppressed migration and EMT processes; Snail, Slug, and Twist (↓) |
| |
| Oxymatrine | RKO cells | 0.25, 0.5, and 0.75 mg/ml | Hinder the CRC cells migration and invasion; N-cadherin, Snail and NF-κB p65 (↓); E-cadherin (↑) |
|
| HCT-8 and HCT-8/5-Fu cells | 2 mg/ml | Reverse EMT program, Snai2, vimentin, and p-NF-κB p65 (↓), E-cadherin (↑) |
| |
| RKO cells | 0.25, 0.5 mg/ml | Inhibit the migration of CRC cells; PAI-1, TGF-β1, α-SMA, FN, Smad4, p-Smad2, and p-P38 (↓); E-cadherin (↑) |
| |
| Apigenin | HCT-116 and LOVO cells xenograft model nude mice | 10, 20 μmol/L | Inhibited tumor metastasis, invasion; NF-κB, Snail, N-cadherin, and vimentin (↓); E-cadherin and occludin (↑) |
|
| 200, 300 mg/kg | ||||
| Genistein | HT-29 cells | 200 μmol/L | Restrain the migratory capability; N-cadherin, Snail2/Slug, ZEB1, ZEB2, FOXC1, FOXC2 and Twist1 (↓); E-cadherin (↑) |
|
| HT-29 cells | 10, 20, and 60 μmol/L | Repress the invasive and metastatic abilities; |
|
Targeting of EMT-related signaling pathways involved in metastatic CRC by medicinal herb extracts in vitro and in vivo.
| Natural herb extracts or polysaccharide | Extraction procedure | Cell lines/animal models | Effective dose | Molecular mechanism | References |
|---|---|---|---|---|---|
|
| 500 g of | HCT-8 cells | 0.125, 0.25, and 0.5 mg/ml | Repress migration and invasion of HCT-8 cells; p-PI3K, PI3K, p-AKT, TGF-β, Smad2/3, Smad4, MMP-1, MMP-2, MMP-3/10, MMP-9, MMP-13 (↓) |
|
| SBPW3 | The crude polysaccharide from | HT-29 cells | 50, 100, and 200 μg/ml | Inhibit the tumor migration and invasion |
|
| CRC metastasis mice model | 100, 200 mg/kg | α-SMA, N-cadherin, p-Smad2, and p-Smad3 (↓); E-cadherin (↑) | |||
|
|
| CT-26 cells colorectal lung metastasis mice model | 1, 5, and 10 μg/ml | Repress the migratory and invasive abilities and reverse EMT program |
|
| 250, 500 mg/kg | N-cadherin, vimentin, Twist, MMP-2 and MMP-9 (↓); E-cadherin (↑) | ||||
|
|
| CT-26 cell lines | 1, 10, and 100 μg/ml | Reduce the tumor migration and invasion ability; N-cadherin, MMP-2, and MMP-9 (↓), E-cadherin (↑) |
|
|
| |||||
| The | |||||
| Ginseng ethanol extract | 100 g of ginseng was decocted in 1 L of ethanol and extracted at 100°C for 3 h. After filtering the ethanol extraction solution, the ethanol solvent was removed by evaporation, and the remaining liquid was freeze-dried | CT-26 and HT-29 cells | 0.2 mg/ml | Inhibit migration and invasion of CRC cells; N-cadherin, vimentin, Snail, MMP-2 and MMP-9 (↓); E-cadherin (↑) |
|
| CT-26 cells-induced lung metastasis model mice | 50 mg/kg |
Targeting of EMT-related signaling pathways involved in metastatic CRC by Chinese herbal formulas in vitro and in vivo.
| Chinese herbal formulas | Main ingredients and proportion | Extraction procedure | Cell lines/animal models | Effective dose | Molecular mechanism | References |
|---|---|---|---|---|---|---|
| Jiedu Sangen Decoction |
| Three medicinal herbs of JSD were mixed and soaked in 1 L of distilled water for 30 min. The filtrates were concentrated to 150 ml to obtain JSD such that its crude drug concentration was 2 g/ml of mother liquor | SW480 cells liver metastasis of colon cancer model mice | 6 mg/ml | Inhibit the invasion and metastasis of CRC cells; N-Cadherin, Yes-associated protein, PDZ-binding motif (↓); E-Cadherin (↑) |
|
| 24 g/kg | ||||||
| CT-26 cells hepatic metastatic CRC mice model | 6 mg/ml | Inhibit tumor migration and invasion; PI3K, AKT, Slug, Snail, N-cadherin, and vimentin (↓); E-cadherin (↑) |
| |||
| 24 g/kg | ||||||
| SW480 and SW620 cells | 6 mg/ml | Repress the invasion and metastasis potential; Snail, Slug, Twist, N-cadherin, vimentin, AKT1, p-AKT1, and p-GSK-3β (↓); E-cadherin (↑) |
| |||
| SW480 cells-induced liver metastasis model mice | 24 g/kg | |||||
| JianPi JieDu Recipe |
| The herb mixtures of JPJD were heated to 100°C for 3 h, and then the decoction was filter, thus aqueous solution was prepared | LoVo cells | 12.5, 25, and 50 μg/ml | Inhibit the invasive and metastatic ability; vimentin, p-Smad2/3, and Snail (↓); Smad2/3 and E-cadherin (↑) |
|
| LoVo cells-induced orthotopic CRC mice model | 250, 500, and 1000 mg/kg | |||||
| Shaoyao decoction |
| Aqueous extracts of Shaoyao decoction were heated in 10 volumes of distilled water ( | SW480 and HCT116 cells | 2, 4 mg/ml | Block EMT process and attenuate proinflammatory cytokines |
|
| AOM/DSS-induced caCRC mice model | 7.12 g/kg | Snail, N-cadherin, fibronectin, and vimentin, as well as IL-1β, IL-6, TNF-α, and NF-κB p65 (↓); E-cadherin (↑) | ||||
| Shenling Baizhu San |
| The medicinal medicines of SBS were decocted at 80°C for 1 h using 10 volumes of distilled water ( | AOM/DSS-induced caCRC mice model | 7.28 g/kg | Inhibit TGF-β1-induced EMT program |
|
|
| Snail, N-cadherin, fibronectin, and vimentin (↓); E-cadherin (↑) | |||||
| Pien-Tze-Huang |
| PZH was obtained from, and authenticated by the sole manufacturer Zhangzhou Pien Tze Huang Pharmaceutical Co. Ltd. | CT-26 cells | 0.25 and 0.5 mg/ml | Hinder the migration and invasion of CT-26 cells and inhibit liver metastasis |
|
| CT-26 cells-induced orthotopic CRC mice model | 234 mg/kg | N-cadherin, TGF-β, p-Smad2/3, and Smad4 (↓); E-cadherin (↑) | ||||
| HCT-8/5-Fu Cells | 0.25, 0.50, and 0.75 mg/ml | Inhibit the migratory and invasive capabilities of HCT-8 cells; TGF-β, Smad4, ZEB1, ZEB2, and N-cadherin (↓) |
| |||
| E-cadherin (↑) | ||||||
| HCT-8 cells | 0.25, 0.50, and 0.75 mg/ml | Repress the tumor migration and invasion; TGF-β1, Smad2/3, Smad4, ZEB1, ZEB2, and N-cadherin (↓); miR-200a, miR-200b, miR-200c, and E-cadherin (↑) |
|
FIGURE 2Chemical structure of the main TCMs active constituents with anti-metastatic CRC efficacy.